Pharma and biotech companies are scratching the surface when deploying artificial intelligence to streamline drug discovery and development. But the AI-enabled drug discovery sector is maturing, according to Chris Gibson, co-founder and CEO of Recursion Pharmaceuticals. More AI validation is coming in 2023 Competition is helping drive the field of AI-enabled drug discovery forward. “Over the last…